Effect of Cannabinoid (THC / CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis (EdomTHC)

David Garcia Cinca

Status and phase

Unknown

Phase 2

Conditions

Endometriosis

Treatments

Drug: Cannabinoid treatment

Study type

Interventional

Funder types

Other

Identifiers

2018-004378-92

Details and patient eligibility

About

This study evaluates the treatment of the symptoms of deep endometriosis with a cannabinoid derivate.

Enrollment

10 estimated patients

Sex

Female

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women between the ages of 18 and 40.
Diagnosis of deep endometriosis after clinical suspicion and confirmation by imaging test.
Pain with a score of 4 or more on a numerical visual scale of 11 levels (EVN 0-10) in the last 3 months (includes any type of pain associated with endometriosis: dysmenorrhea, dyspareunia, dyschezia, dysuria and / or pelvic pain).
Women of childbearing age * should have a negative pregnancy test before inclusion in the study and should commit to using highly effective contraceptive methods (hormonal contraceptives, intrauterine device, intrauterine hormonal release systems, bilateral tubal occlusion, vasectomy the couple, barrier methods and sexual abstinence) during the entire duration of the study and up to 3 months after the end of it.
Acceptance of participation in the study by signing the informed consent.

Exclusion criteria

Patients previously submitted to open abdominal surgery.
History of cancer.
Suspicion or diagnosis of endocrine, cardio-vascular or systemic pathology relevant.
Pregnancy or anticipation of pregnancy up to 3 months after the end of the study.
Current breastfeeding.
Use of hormonal treatment (combined oral contraception, progestin in the 3 months prior to the study, GNRH analogs in the 6 months prior to the start of the study).
Use of other analgesics different from those allowed in the study.
Recreational or pharmacological use of cannabinoids.
Hypersensitivity to cannabinoids or any of the exceptions.
Known or suspected personal history, or family history of schizophrenia or other psychotic illnesses, severe personality disorder or other major psychiatric disorders.
Patients with liver or kidney failure, severe cardiovascular disease and a history of epilepsy or recurrent seizures.
Patients who use concomitant potent enzyme inducers of CYP3A4, such as rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John's wort.